EnWave Announces Successful Test Results For Antibodies Using freezeREV Dehydration Technology

EnWave Corporation (TSX VENTURE: ENW.V) ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology. Results from this study showed no detectable visual difference between freezeREV-dried and freeze dried samples when examined with the SDS-PAGE electrophoresis method. Additionally, the indication of the molecular weight was similar between the two dried samples and liquid antibodies. Freeze drying, or lyophilization, is the current industry standard for dehydrating live or active organisms such as antibodies.

Freeze drying can be particularly harsh on sensitive materials such as antibodies because of the length of time the organisms are exposed to extremely low temperatures.

Tiens Biotech Group (USA) Reports Record Twelve-Month Results

Tiens Biotech Group (USA), Inc. (the "Company" or "Tiens", NYSE AlternextUS: TBV), http://www.tiens-bio.com , today announced record financial results for the twelve months ended December 31, 2008.

For the twelve months ended December 31, 2008, revenue was $77.2 million, an increase of 40.7% compared to $54.9 million for the twelve months ended December 31, 2007.

Net income for the twelve months ended December 31, 2008 was $27.7 million, or $0.39 per share, compared to $17.9 million, or $0.25 per share for the twelve months ended December 31, 2007.

NOVEL FOOD and PARNUTS approval granted for NKO(R) opens the 2nd largest nutraceutical market for Neptune

Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce today that the European Food Safety Association (EFSA) has approved Neptune Krill Oil (NKO(R)) as a NOVEL FOOD and PARNUTS for commercialization in the European Union.

NKO(R) has successfully passed rigorous regulatory review and scrutiny by all member states of the European Union (EU), which approved NKO(R) as a NOVEL FOOD and PARNUTS allowing its immediate commercialization at a clinically proven effective daily dose in all 27 European countries.

CV Technologies Announces Strong Return to Profitability and Double Digit Revenue Growth in Fiscal 2008

CV Technologies Inc. (TSX:CVQ) today announced that revenue for the fiscal year ended September 30, 2008 rose 17.5% to $49.4 million from $42.0 million in fiscal 2007. Net earnings increased to $4.6 million ($0.04 per common share) in fiscal 2008, a $14.4 million improvement from the fiscal 2007 net loss of $9.8 million ($0.09 loss per common share).

"CV Technologies achieved its growth and profitability goals for fiscal 2008, including its publicly stated objective of achieving a double digit sales increase," said Executive Chairman Jack Moffatt. "In fact, we have achieved our key goals in the 12 months since adopting our five-year strategic business plan that addresses all aspects of our business.